Join us on Tuesday, February 9^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Novartis, Puma Biotechnology Inc and Seagen Inc.

Tuesday, February 9, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

PART I: HER2-POSITIVE BREAST CANCER

• Long-term efficacy outcomes and optimal use of anthracycline- and nonanthracycline-based neoadjuvant regimens
• Selection of adjuvant anti-HER2 therapy for patients receiving or not receiving neoadjuvant therapy
• Current role of neratinib as extended-adjuvant therapy; patient selection and clinical factors (eg, ER/PR status, tumor size, nodal status) guiding its use in practice
• Available clinical research data leading to the FDA approval of the fixed-dose subcutaneous pertuzumab/trastuzumab combination; optimal integration into clinical management
• Clinical and biologic factors in the selection of first- and later-line therapy for patients with HER2-positive metastatic breast cancer (mBC)
• Available efficacy and safety findings from the Phase III NALA study of neratinib/capecitabine or lapatinib/capecitabine for patients with HER2-positive mBC; FDA approval and current nonresearch role
• Efficacy and safety data from the Phase II DESTINY-Breast01 trial leading to the FDA approval of trastuzumab deruxtecan for HER2-positive mBC; optimal integration into practice
• Biologic rationale for, available data with and ongoing investigation of trastuzumab deruxtecan for patients with HER2-low advanced breast cancer
• Activity and safety of tucatinib with trastuzumab/capecitabine in patients with HER2-positive mBC in the pivotal Phase II HER2CLIMB trial; optimal integration into treatment algorithms
• Intracranial efficacy and clinical outcomes with tucatinib/trastuzumab/capecitabine; current role of tucatinib for patients with HER2-positive brain metastases
• Spectrum, frequency, severity and management of common toxicities associated with novel HER2-directed therapies

PART 2: ER-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER (TNBC)

• Design, eligibility criteria and key efficacy and safety endpoints of Phase III trials (eg, monarchE, NATALEE, PALLAS, PENELOPE-B) exploring the potential role of adjuvant CDK4/6 inhibition in therapy for ER-positive early breast cancer
• Improvement of invasive disease-free survival with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, node-positive, ER-positive, HER2-negative early breast cancer in the monarchE trial; implications for ongoing research and clinical practice
• Key data sets and guideline recommendations informing the selection of adjuvant therapy for patients with ER-positive, HER2-negative node-negative and node-positive early breast cancer
• Available research database with and current clinical role of CDK4/6 inhibitors for ER-positive mBC
• Published research findings with and FDA approval of alpelisib/fulvestrant for patients with PIK3CA mutations; optimal incorporation into current management algorithms
• Other novel agents and strategies under investigation for patients with ER-positive mBC (eg, venetoclax, capivasertib)
• FDA approval of atezolizumab/nab paclitaxel as first-line therapy for patients with PD-L1-positive metastatic TNBC; optimal integration into management algorithms
• Design, eligibility criteria and key efficacy and safety findings from the Phase III KEYNOTE-355 trial evaluating chemotherapy with or without pembrolizumab for patients with previously untreated metastatic TNBC; recent FDA approval and potential role of pembrolizumab/chemotherapy for patients with metastatic TNBC
• Key efficacy and safety findings with neoadjuvant anti-PD-1/PD-L1 antibodies in combination with chemotherapy for TNBC; current nonresearch role, if any
• Phase III data sets supporting the FDA approvals of olaparib and talazoparib for mBC with BRCA germline mutation; current role for patients with DNA damage repair abnormalities beyond BRCA1/2
• Mechanism of action, available data and FDA approval of sacituzumab govitecan; optimal integration into TNBC management algorithms
• Other novel agents and strategies under investigation for patients with TNBC

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
• Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
• Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
• Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
• Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, comorbidities, symptomatology and extent and sites of disease.
• Review published research data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed PD-L1-positive metastatic triple-negative breast cancer, and use this information to make treatment recommendations.
• Recall available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized triple-negative breast cancer, and determine the current and potential role of these strategies in clinical practice.
• Assess potential biomarkers of response to PARP inhibition, and use this information to optimize the selection of available genetic testing platforms and related therapeutic interventions for patients with metastatic breast cancer.
• Appraise recent FDA approvals and ongoing clinical research of novel agents and treatment strategies for various forms of breast cancer, and counsel patients about protocol and nonresearch treatment recommendations.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Burstein and Dr Carey have no relevant conflicts of interest to disclose.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Novartis, Puma Biotechnology Inc and Seagen Inc.